Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

Aspirin, salicylates, and cancer

Elwood, Peter Creighton, Gallagher, Alison M., Duthie, Garry G., Mur, Luis A. J. and Morgan, Gareth 2009. Aspirin, salicylates, and cancer. The Lancet 373 (9671) , pp. 1301-1309. 10.1016/S0140-6736(09)60243-9

Full text not available from this repository.


Evidence from a wide range of sources suggests that individuals taking aspirin and related non-steroidal anti-infl ammatory drugs have reduced risk of large bowel cancer. Work in animals supports cancer reduction with aspirin, but no long-term randomised clinical trials exist in human beings, and randomisation would be ethically unacceptable because vascular protection would have to be denied to a proportion of the participants. However, opportunistic trials of aspirin, designed to test vascular protection, provide some evidence of a reduction in cancer, but only after at least 10 years. We summarise evidence for the potential benefi t of aspirin and natural salicylates in cancer prevention. Possible mechanisms of action and directions for further work are discussed, and implications for clinical practice are considered.

Item Type: Article
Date Type: Publication
Status: Published
Schools: Medicine
Subjects: R Medicine > R Medicine (General)
R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer)
Publisher: Elsevier
ISSN: 0140-6736
Last Modified: 04 Jun 2017 03:44

Citation Data

Cited 219 times in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item